These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38260304)

  • 1. Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants.
    Johnston TS; Li SH; Painter MM; Atkinson RK; Douek NR; Reeg DB; Douek DC; Wherry EJ; Hensley SE
    medRxiv; 2024 Jan; ():. PubMed ID: 38260304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants.
    Johnston TS; Li SH; Painter MM; Atkinson RK; Douek NR; Reeg DB; Douek DC; Wherry EJ; Hensley SE
    Immunity; 2024 Apr; 57(4):912-925.e4. PubMed ID: 38490198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.
    Muik A; Lui BG; Quandt J; Diao H; Fu Y; Bacher M; Gordon J; Toker A; Grosser J; Ozhelvaci O; Grikscheit K; Hoehl S; Kohmer N; Lustig Y; Regev-Yochay G; Ciesek S; Beguir K; Poran A; Vogler I; Türeci Ö; Sahin U
    Cell Rep; 2023 Aug; 42(8):112888. PubMed ID: 37527039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans.
    Tortorici MA; Addetia A; Seo AJ; Brown J; Sprouse K; Logue J; Clark E; Franko N; Chu H; Veesler D
    Immunity; 2024 Apr; 57(4):904-911.e4. PubMed ID: 38490197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 Variants Omicron BA.4/5 and XBB.1.5 Significantly Escape T Cell Recognition in Solid-organ Transplant Recipients Vaccinated Against the Ancestral Strain.
    Halvorson T; Ivison S; Huang Q; Ladua G; Yotis DM; Mannar D; Subramaniam S; Ferreira VH; Kumar D; Belga S; Levings MK;
    Transplantation; 2024 Apr; 108(4):e49-e62. PubMed ID: 38012843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent immune imprinting after XBB.1.5 COVID vaccination in humans.
    Tortorici MA; Addetia A; Seo AJ; Brown J; Sprouse KR; Logue J; Clark E; Franko N; Chu H; Veesler D
    bioRxiv; 2023 Nov; ():. PubMed ID: 38076876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
    Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
    Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continued evasion of neutralizing antibody response by Omicron XBB.1.16.
    Faraone JN; Qu P; Zheng YM; Carlin C; Jones D; Panchal AR; Saif LJ; Oltz EM; Gumina RJ; Liu SL
    Cell Rep; 2023 Oct; 42(10):113193. PubMed ID: 37777967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
    Chalkias S; McGhee N; Whatley JL; Essink B; Brosz A; Tomassini JE; Girard B; Edwards DK; Wu K; Nasir A; Lee D; Avena LE; Feng J; Deng W; Montefiori DC; Baden LR; Miller JM; Das R
    J Infect Dis; 2024 Aug; 230(2):e279-e286. PubMed ID: 38349280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2.
    He C; Alu A; Lei H; Yang J; Hong W; Song X; Li J; Yang L; Wang W; Shen G; Lu G; Wei X
    MedComm (2020); 2023 Jun; 4(3):e263. PubMed ID: 37125241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 Neutralization Capacity in Hemodialysis Patients with and without a Fifth Vaccination with the Updated Comirnaty Original/Omicron BA.4-5 Vaccine.
    Liao BH; Platen L; Grommes M; Cheng CC; Holzmann-Littig C; Christa C; Haller B; Kappler V; Bester R; Werz ML; Platen E; Eggerer P; Tréguer L; Küchle C; Schmaderer C; Heemann U; Renders L; Protzer U; Braunisch MC
    Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3.
    Faraone JN; Qu P; Goodarzi N; Zheng YM; Carlin C; Saif LJ; Oltz EM; Xu K; Jones D; Gumina RJ; Liu SL
    Emerg Microbes Infect; 2023 Dec; 12(2):2270069. PubMed ID: 37819267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 BA.1 and BA.2 breakthrough infections boost antibody responses to early Omicron subvariants but not BQ.1.1 or XBB.1.5.
    Abbad A; Yellin T; Singh G; Fried M; Raskin A; Tcheou J; Monahan B; Gleason C; ; Simon V; Carreño JM; Krammer F
    Cell Rep Med; 2024 Mar; 5(3):101474. PubMed ID: 38508136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.
    Li P; Liu Y; Faraone JN; Hsu CC; Chamblee M; Zheng Y-M; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu S-L
    mBio; 2024 May; 15(5):e0075124. PubMed ID: 38591890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
    Hu Y; Zou J; Kurhade C; Deng X; Chang HC; Kim DK; Shi PY; Ren P; Xie X
    Emerg Microbes Infect; 2023 Dec; 12(2):2271089. PubMed ID: 37824708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.
    Machado RRG; Candido ÉD; Aguiar AS; Chalup VN; Sanches PR; Dorlass EG; Amgarten DE; Pinho JRR; Durigon EL; Oliveira DBL
    Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
    Cheng SMS; Mok CKP; Li JKC; Chan KKP; Luk KS; Lee BHW; Gu H; Chan KCK; Tsang LCH; Yiu KYS; Ling KKC; Tang YS; Luk LLH; Yu JKM; Pekosz A; Webby RJ; Cowling BJ; Hui DSC; Peiris M
    Virol J; 2024 Mar; 21(1):70. PubMed ID: 38515117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants.
    Qu P; Xu K; Faraone JN; Goodarzi N; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Gumina RJ; Liu SL
    Cell; 2024 Feb; 187(3):585-595.e6. PubMed ID: 38194968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB.
    He Q; Wu L; Xu Z; Wang X; Xie Y; Chai Y; Zheng A; Zhou J; Qiao S; Huang M; Shang G; Zhao X; Feng Y; Qi J; Gao GF; Wang Q
    Cell Rep Med; 2023 Apr; 4(4):100991. PubMed ID: 37019110
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.